BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced primary results from the pivotal Phase 3 GLOW study evaluating fixed-duration IMBRUVICA® plus venetoclax compared to chlorambucil plus obinutuzumab for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The Janssen Pharmaceutical announced overall survival results from the Phase 3 MAIA study showing the addition of DARZALEX® to lenalidomide and dexamethasone resulted in a statistically significant survival benefit over lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression.

Kite, a Gilead Company, announced follow-up results from the pivotal ZUMA-5 trial of Yescarta® – the first and only CAR T-cell therapy approved in patients with relapsed or refractory indolent follicular lymphoma.

As the global nonprofit leader in Alzheimer’s research and science we have extensively reviewed the clinical trial data for Aduhelm™.

AbbVie announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA® plus VENCLEXTA®/VENCLYXTO® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria.

First presentation of long-term safety and disease control data from Phase 3 TRuE-AD studies of ruxolitinib cream in atopic dermatitis

Core One Labs Inc., is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc., a company operating under one of few Health Canada Controlled Drugs and Substances Dealer’s labs, is pleased to announce that it is in the final stages of completing its provisional patent application for the protection of its proprietary biosynthetic psilocybin production system.